US House ban on pay-for-delay settlements upsets pharma
This article was originally published in Scrip
The US House of Representatives has cleared a controversial measure that, if signed into law, would ban "pay for delay" settlements between brand-name pharmaceutical companies and their generic competitors aimed at delaying the entry of generic medicines onto the market.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.
Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’
Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.